Medication info

Pregabalin Capsule 75 mg (Pregabalin)

Prescription medicationHard capsuleOralApproval withdrawn
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
You & Life Sciences Co., Ltd.
Appearance
A hard capsule with a brownish upper part and white lower part containing a white powder
Packaging
30 capsules/bottle, 60 capsules/bottle
Approval status
Approval withdrawn

MFDS item code 202003820 · Approved 2020.05.26

This product's status changed to Approval withdrawn on 2025.02.27. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures
Who takes it
Adults · Children
Adult dose
This medicine is administered orally as pregabalin in 2 divided doses per day, regardless of food. Since this medicine is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Total daily dose of pregabalinᵃ Initial dose (mg/day) 150, maximum dose (mg/day) 600, dosing regimen BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Total daily dose of pregabalinᵃ Initial dose (mg/day) 75, maximum dose (mg/day) 300, dosing regimen BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Total daily dose of pregabalinᵃ Initial dose (mg/day) 25-50, maximum dose (mg/day) 150, dosing regimen QD or BID Creatinine clearance (CLcr), (mL/min) <15: Total daily dose of pregabalinᵃ Initial dose (mg/day) 25, maximum dose (mg/day) 75, dosing regimen QD Supplemental dose after hemodialysis: Initial dose (mg/day) 25, maximum dose (mg/day) 100, dosing regimen Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: The supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (65 years of age and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Use is not recommended because sufficient safety and efficacy data are not available. Adolescents aged 12-17 years: Use is not recommended because sufficient safety and efficacy data are not available.

Ingredients

Manufacturer
You & Life Sciences Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat pain caused by peripheral and central neuropathies in adults. It also helps to manage partial seizures in adult patients with epilepsy as an adjunct therapy. Finally, it is effective in alleviating pain associated with fibromyalgia. These efficacies are utilized to improve nerve-related pain and seizures.

How to take

Adult dose

This medicine is administered orally as pregabalin in 2 divided doses per day, regardless of food. Since this medicine is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Total daily dose of pregabalinᵃ Initial dose (mg/day) 150, maximum dose (mg/day) 600, dosing regimen BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Total daily dose of pregabalinᵃ Initial dose (mg/day) 75, maximum dose (mg/day) 300, dosing regimen BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Total daily dose of pregabalinᵃ Initial dose (mg/day) 25-50, maximum dose (mg/day) 150, dosing regimen QD or BID Creatinine clearance (CLcr), (mL/min) <15: Total daily dose of pregabalinᵃ Initial dose (mg/day) 25, maximum dose (mg/day) 75, dosing regimen QD Supplemental dose after hemodialysis: Initial dose (mg/day) 25, maximum dose (mg/day) 100, dosing regimen Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: The supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (65 years of age and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Use is not recommended because sufficient safety and efficacy data are not available. Adolescents aged 12-17 years: Use is not recommended because sufficient safety and efficacy data are not available.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so mood changes or unusual behaviors should be carefully monitored during treatment. Do not take this medication if you have an allergy to any of its components or specific genetic disorders such as lactose intolerance. Diabetic patients may need to adjust the dosage of blood sugar control medication due to weight gain, and treatment should be discontinued immediately if symptoms of angioedema appear. Elderly patients should be especially cautious at the beginning of treatment due to the risk of dizziness or drowsiness, which could lead to falls or injuries. Consult with a healthcare professional if symptoms such as blurred vision or changes in vision occur. When discontinuing the medication, withdrawal symptoms such as insomnia, headache, nausea, and anxiety may occur, so abrupt cessation should be avoided. Patients with a history of substance abuse require special caution when taking this medication due to the risks of drug abuse. Patients with decreased kidney function may require dose adjustments, and those with heart disease should consult their healthcare provider before taking this medication. Concurrent use of this drug with opioid analgesics may increase the risk of central nervous system depression, so caution is advised. During early pregnancy, there may be risks to the fetus, so pregnant women should avoid taking it, and women of childbearing age should use effective contraception. Women who are breastfeeding should consult their healthcare provider about whether to discontinue breastfeeding or the medication, as this drug may be transmitted through breast milk. Dizziness and drowsiness may occur while taking this medication, so caution is needed when driving or operating dangerous machinery. In case of overdose, symptoms such as confusion, drowsiness, depression may appear, and treatment such as blood dialysis may be necessary. Store out of reach of children, and do not transfer to another container for safety.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral edema
  • upper airway edema
  • dizziness
  • drowsiness
Show 179 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • visual changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • suicidal ideation
  • pain
  • seizures
  • sweating
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • impaired respiratory function
  • vomiting
  • abdominal distention
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory impairment
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • joint pain
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle stiffness
  • rhabdomyolysis
  • urinary disorders
  • urinary incontinence
  • reduced urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • breast discharge
  • gynecomastia
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling intoxicated
  • sensory abnormalities
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased potassium level
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • nasopharyngitis
  • neutropenia
  • increased appetite
  • appetite loss
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • relief
  • decreased libido
  • depersonalization
  • hypersexuality
  • agitation
  • mood swings
  • emotional distress
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • apathy
  • ataxia
  • motor coordination abnormalities
  • balance disorder
  • amnesia
  • attention disorder
  • memory impairment
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory reduction
  • sedation
  • hypersomnia
  • cognitive impairment
  • nystagmus
  • speech disorder
  • myoclonus
  • diminished reflexes
  • motor abnormalities
  • psychomotor agitation
  • positional vertigo
  • hypersensitivity
  • burning sensation
  • activity tremor
  • syncope
  • confusion
  • motor retardation
  • olfactory abnormalities
  • loss of taste
  • writing difficulties
  • diplopia
  • dizziness
  • auditory hypersensitivity
  • first-degree heart block
  • tachycardia
  • bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • nasal hemorrhage
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • keratitis
  • pulmonary edema
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • state of confusion
  • agitation
  • restlessness
  • worsening of seizures
  • shock
  • symptoms resembling anaphylaxis
  • mucous membrane syndrome
  • erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is advisable to maintain the storage temperature between 15 and 30 degrees Celsius to preserve the medication's effectiveness.

Appearance and packaging

Appearance

A hard capsule with a brownish upper part and white lower part containing a white powder

Package unit

30 capsules/bottle, 60 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.